BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Menopause Drugs From Depomed, Inc. (DEPO), Hisamitsu Pharmaceutical Offer Benefits


3/1/2013 8:02:38 AM

Drugs being developed by Depomed Inc. (DEPO) and Hisamitsu Pharmaceutical Co. (4530) to ease menopausal hot flashes yielded inconsistent results in trials that call into question how meaningful the benefits would be, regulators said. Depomed’s gabapentin and Hisamitsu’s paroxetine mesylate were shown to help women avoid sudden feverish feelings linked to menopause, staff at the Food and Drug Administration said in a report today. The concern is that the reduction in severity and frequency of the flashes varied widely in clinical trials. Each drug, non-hormonal alternatives to the existing medicines, will be discussed on March 4 by agency advisers. Companies have been looking to give women more choices in menopause therapies after hormone treatments were found to increase the risk of breast cancer, heart attack and stroke. “There’s a real need for an approved product so women who don’t want to use hormones don’t have to suffer in silence,” Michael Sweeney, chief medical officer for Menlo Park, California-based Depomed, said in a telephone interview. Hot flashes affect about 32 million women in the U.S. and 40 percent choose not to use hormones or aren’t good candidates for them, Depomed said. The FDA is scheduled to decide on Depomed’s pill by May 31 and Saga, Japan-based Hisamitsu’s capsule by June 28. Suicidal Thoughts: Both drugs also carry side effects that include suicidal thoughts, which need to be considered before approval, the staff members said. The suicidal thoughts are listed as side effects in existing drugs with the same active ingredients. Hisamitsu’s paroxetine mesylate is currently sold in the antidepressant Pexeva, and Depomed’s gabapentin is used in a shingles therapy.

Read at Bloomberg
Read at Reuters
Read at News Release
Read at MedPageToday

   
Menopause

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES